Tackling Mechanisms Of Disease Resistance At Janssen
Executive Summary
“We see the whole market really changing over the next 10 years to reflect more and more use of mechanisms other than anti-TNFs,” Sue Dillon says.
You may also be interested in...
The Future Of Oncology At J&J: An Interview With William Hait
The pharmaceuticals business is riding high at Johnson & Johnson, posting impressive gains from new launches in immunology and cancer – in particular, the May launch of Zytiga (abiraterone acetate) in the U.S. for metastatic castration-resistant prostate cancer.
Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question
Pfizer Inc. on Sept. 8 released some data from three previously undisclosed pivotal trials for tofacitinib, its high-profile, first-in-class JAK3 inhibitor for rheumatoid arthritis, which it says shows that the drug is equal in efficacy to Abbott Laboratory Inc.’s bestselling TNF inhibitor Humira.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.